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Abstract
Background: Chronic kidney disease (CKD), including nephrotic syndrome, is a major cause of cardiovascular
morbidity and mortality. The literature indicates that CKD is associated with profound lipid disorders due to the
dysregulation of lipoprotein metabolism which progresses kidney disease. The objective of this study is to evaluate
the protective effects of curcumin on dyslipidaemia associated with adenine-induced chronic kidney disease in rats.
Methods: Male SD rats (n = 29) were divided into 5 groups for 24 days: normal control (n = 5, normal diet), CKD
control (n = 6, 0.75% w/w adenine-supplemented diet), CUR 50 (n = 6, 50 mg/kg/day curcumin + 0.75% w/w
adenine-supplemented diet), CUR 100 (n = 6, 100 mg/kg/day curcumin + 0.75% w/w adenine-supplemented diet),
and CUR 150 (n = 6, 150 mg/kg/day curcumin + 0.75% w/w adenine-supplemented diet). The serum and tissue lipid
profile, as well as the kidney function test, were measured using commercial diagnostic kits.
Results: The marked rise in total cholesterol, low-density lipoprotein (LDL) cholesterol, very low-density lipoprotein
(VLDL) cholesterol, triglycerides and free fatty acids in serum, as well as hepatic cholesterol, triglyceride and free
fatty acids of CKD control rats were significantly protected by curcumin co-treatment (at the dose of 50, 100 and
150 mg/kg). Furthermore, curcumin significantly increased the serum high-density lipoprotein (HDL) cholesterol
compared to the CKD control rats but did not attenuate the CKD-induced weight retardation. Mathematical computational
analysis revealed that curcumin significantly reduced indicators for the risk of atherosclerotic lesions (atherogenic index) and
coronary atherogenesis (coronary risk index). In addition, curcumin improved kidney function as shown by the reduction in
proteinuria and improvement in creatinine clearance.
Conclusion: The results provide new scientific evidence for the use of curcumin in CKD-associated dyslipidaemia and
substantiates the traditional use of curcumin in preventing kidney damage.
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Background
Chronic kidney disease (CKD) encompasses a spectrum of
pathophysiological processes associated with abnormal
kidney function (such as proteinuria) and a progressive
decline in glomerular filtration rate. CKD is a substantial
health problem, and its prevalence is increasing worldwide
at least in part, due to a rise in the prevalence of systemic
diseases such as metabolic syndrome that damage the kid-
ney function [1, 2].
It is well documented that cardiovascular disease, such
as heart failure or coronary artery disease, is one of the
leading causes of mortality in patients with CKD. Thus,
most patients with CKD die of the cardiovascular disease
before dialysis becomes necessary [3–5]. CKD is associ-
ated with cardiovascular complications such as dyslipi-
daemia, atherosclerosis and myocardial infarction [6].
Patients and experimental animals with CKD have a high
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plasma concentration of lipid markers such as choles-
terol, tryglycerides and fatty acids [7, 8].
The current therapeutic regimens including the use of
statins and fibrates have limited success in treating the
associated dyslipidaemia of CKD and do not address the
underlying causal factors [9]. Although statins can be ef-
fective in slowing CKD progression in patients with
mild-to-moderate CKD, they have consistently failed to
alleviate HDL deficiency [9, 10]. Fibrates are indicated
when hypertriglyceridaemia is the primary lipid abnor-
mality in the CKD patient and may reduce triglyceride
levels significantly [10]. However, fibrates are excreted
by the kidney and may cause myositis, particularly when
used in conjunction with statins [11]. Therefore, the de-
velopment of novel therapies to either slow or reverse
the deterioration in kidney function, as well as amelior-
ate the metabolic dyslipidaemia of CKD, is highly
needed. Natural products have shown significant poten-
tial in improving hepatic lipid metabolism in
experimentally-induced CKD [12–15].
Curcumin [1,7-bis (4-hydroxy-3-methoxyphenyl)-1,6-
heptadiene-3,5-dione] is produced in the rhizome of
the plant Curcuma longa L. and is a major poly-
phenolic chemical component of turmeric powder
[16]. The pharmacokinetic, pharmacodynamics and
clinical pharmacological properties of curcumin have
been extensively studied over the past six decades.
The effects of curcumin on renal damage have been
investigated both in vivo and in vitro. In laboratory
animals, chronic supplementation of curcumin has
been shown to protect renal damage in various
chemically-induced nephrotoxicity and renal injury
models [17–29]. Curcumin has also been shown to
possess renoprotective effects against various metal-
induced nephrotoxicity [30–33]. In addition, the daily
administration of curcumin has been shown to reduce
proteinuria, glomerulosclerosis, tubule-interstitial in-
jury and subsequently, renal failure in 5/6 nephrecto-
mised rats [34–38]. Furthermore, curcumin has been
shown to protect renal damage in streptozotocin-
(STZ) [39–41], STZ-nicotinamide [42] and ischaemia-
reperfusion-induced of CKD rat models [43]. In
addition, curcumin has shown cardioprotective effects
by attenuating chronic renal failure-induced cardiac
hypertrophy and remodelling in 5/6 nephrectomised
rats [44–46]. Recently, Abeer and El-Mahalaway [47]
demonstrated that the daily administration of curcu-
min protected against aflatoxin-induced renal cortical
damage in Wistar rats. Jacob et al. [48] observed that
curcumin administration reduced glomerulonephritis
injury inflammation and fibrosis and improved renal
function in mice. In an in vitro study performed by
Waly et al. [49], curcumin markedly protected the hu-
man embryonic kidney cell from cisplatin-and
oxaliplatin-induced oxidative stress. In addition, cur-
cumin has been shown to protect renal tissue from fi-
brosis by suppressing the transforming growth factor-
β (TGF- β) in vitro [50].
Apart from renoprotective effects, a number of anti-
dyslipidaemic activities of curcumin have been reported
in diet- and/or chemical-induced dyslipidaemic animal
models [51]. Furthermore, curcumin has shown signifi-
cant potential in improving hepatic lipid metabolism in
the non-CKD dyslipidaemic population [52, 53]. A re-
cent study showed that curcumin ameliorates renal dam-
age and oxidative stress in adenine-induced CKD in rats
[54]. However, no study has examined the effects of cur-
cumin on hepatic lipid alteration in experimentally in-
duced CKD. Thus, the aim of the study was to examine
the effects of increasing concentrations of curcumin on
the various biochemical parameters involved in lipid me-
tabolism of a chemically-induced CKD rat model to fur-
ther support curcumin’s use in CKD.
Methods
Chemicals and apparatus used
Curcumin (> 94%) was purchased from Sigma (St. Louis,
MO, USA). The diagnostic kits of cholesterol, triglycer-
ides, HDL-cholesterol, albumin, creatinine and urea nitro-
gen were obtained from PM Separations (Capalaba DC,
USA), while the non-esterified free fatty acid kit was ob-
tained from Wako Diagnostics. Both the standard
(AIN93G) and the adenine (0.75% w/w)-supplemented
(SF15–082) rat pellet diets were supplied by Speciality
Feeds (Glen Forrest, WA, Australia). The standard diet
contained (in weight percentage) approximatley: 60%
carbohydrate, 17.5% protein, 5% fat, 7% crude fibre, and
the adenine-supplemented diet contained 0.75% adenine,
in addition to the standard diet. All other chemicals were
of analytical or higher grade from Sigma-Aldrich (St
Louis, MO, USA), unless otherwise specified. A UV-VIS
spectrophotometer (Ultrospec 2000, Biochrom Ltd., Cam-
bridge, UK) was used for all absorbance measurements.
Animals
In the present study, twenty-nine (29) adult male
Sprague-Dawley rats with an average body weight of
150–200 g were used in polypropylene cages (3 rats per
cage to minimise isolation stress) with water ad libitum
and 12 h light/dark cycle in a temperature controlled fa-
cility at 24 ± 2 °C having 50–60% relative humidity. The
rats were acclimatised to the laboratory conditions for
one week prior to experimentation. The use and care of
the animals in this experimental protocol was approved
by the Institutional Animal Care and Ethics Committee
(Approval Number: A11259) of Western Sydney Univer-
sity, Australia following the National Health and Medical
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Research Council (NHMRC) guidelines on the “Austra-
lian Code of Practice for the Care and Use of Animals
for Scientific Purposes”.
Experimental design and treatments
The sample size (number of rats per group) calculation
in the present study was carried out using the “resource
equation method” [55]. In this method, a value ‘E’ that indi-
cates the sample size is measured which is the degrees of free-
dom of analysis of variance (ANOVA). The ‘E’ value is
calculated by subtracting the total number of experimental
groups from the total number of experimental animals. The
rats were weight matched and randomly divided into five
groups (n = 5 to 6 per group) and received the following
treatments: Group 1 received 1% sodium carboxy methyl cel-
lulose (CMC) together with standard diet and served as con-
trol; Group 2–5 received adenine-supplemented diet (0.75%
w/w adenine in standard diet) to induce chronic kidney dis-
ease. In addition to adenine-supplemented diet, Group 2 re-
ceived 1% sodium CMC and served as the CKD control;
Group 3–5 received curcumin at doses of 50, 100 and 150
mg/kg (dissolved in 1% sodium CMC), respectively. All treat-
ments were given by oral gavage once daily for 24 days. On
day-21, the rats were placed individually in metabolic cages,
acclimatised for two days and the 24 h faeces and urine were
collected on day-24 (Fig. 1). The urine samples were centri-
fuged at 1000 rpm for 10min to remove food particles and
debris, and the supernatants were stored at − 20 °C until ana-
lysis. The rats were anesthetised with an intraperitoneal injec-
tion of ketamine (75mg/kg) and xylazine (5mg/kg) cocktail,
and blood samples (approximately 3mL) were collected from
a cardiac puncture and allowed to clot for 30min before cen-
trifuging at 3000 rpm for 15min. The serum was separated
and stored at − 20 °C until biochemical analysis. After blood
collection, the liver and kidney of each rat were immediately
dissected, weighed and snap frozen in liquid nitrogen and
stored at − 80 °C until biochemical analysis. At the end of the
procedure, the rats were euthanised by exsanguination from
the abdominal aorta.
Biochemical estimations
Body weight, food intake and water intake
The daily body weights of all rats were recorded daily at
4 PM for 24 days. The 24 h food and water intakes from
each cage were determined daily at 10 AM.
Determination of serum biochemical parameters
Serum total cholesterol, triglycerides, HDL-cholesterol,
NEFA, urea nitrogen, albumin and creatinine were esti-
mated as described [56] earlier using the commercial
diagnostic kits following the manufacturer’s instructions.
Serum VLDL and LDL-cholesterol were calculated indir-
ectly by the Friedewald’s equations.
VLDL = Triglycerides/5; LDL = Total-cholesterol –
[HDL + VLDL].
Atherogenic index (AI) and coronary risk index (CRI)
as measures of the extent of atherosclerotic lesions and
coronary atherosclerosis development, respectively, were
calculated using serum total cholesterol and HDL chol-
esterol of different groups of rats using the mathematical
formulae below [56].
AI = [Total cholesterol- HDL]/HDL; CRI = Total chol-
esterol/HDL.
Determination of urine biochemical parameters
Total urinary protein (proteinuria) was estimated based
on the method of Bradford following the manufacturer’s
instructions (Bio-Rad, Hercules, CA, USA), with absorb-
ance measured at 595 nm using Thermo Multiskan mi-
croplate reader. Urine creatinine and urea nitrogen
(UUN) were estimated using the commercial diagnostic
kits following the manufacturer’s instructions. Creatinine
clearance was mathematically calculated as a clinical
index of kidney function using serum and urine creatin-
ine values as per the following formula [57].
Fig. 1 Schematic representation of experimental protocol
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[Urine creatinine (mg/dL) × urine volume (mL)/serum
creatinine (mg/dL)] × [1000/body weight (g)] × [1/1440
(min)].
Determination of hepatic lipids
Total lipids were extracted from the liver tissues by the
modified method of Hara and Radin [58]. Briefly, 75–100
mg aliquots of liver tissue were homogenised in 20 vol-
umes of isopropanol, shaken on orbital shaker for 45min
and centrifuged at 3000 x g for 15min. The separated su-
pernatants were analysed for hepatic total cholesterol, tri-
glycerides and NEFA using commercial diagnostic kits.
Data and statistical analysis
All the results are expressed as mean ± SEM. To analyse
the quantitative differences among the experimental groups
before or after treatments, the respective data was subjected
to analysis of variance (ANOVA) using Graphpad Prism
(version 6.0) statistical programme. Post-hoc comparisons
were made using Dunnett’s multiple comparisons test. Stat-
istical differences in individual groups before and after
treatments were detected using Student’s paired t-test. In
all tests, p < 0.05, p < 0.01 and p < 0.001 were used as the
criterion criteria for statistical significance.
Results
Body weight
There was no significant difference in the initial body
weights (194.2 ± 5.7 g to 198.8 ± 2.4 g; n = 5 to 6) among
the different groups (Fig. 2 a). While the normal control
rats (n = 5) exhibited a significant increase (380.4 ± 6.0 g
vs 194.2 ± 5.7 g; p < 0.001) in body weight compared with
their pre-treated values at the end of the 24 days, neither
Fig. 2 Effect of curcumin on adenine-induced body weight change in rats (A) Daily recordings of the mean body weight of the experimental
groups of rats and (B) comparison of the mean body weights of rats prior to (open columns) and after treatment (closed columns) either with
the adenine-supplemented diet alone or with curcumin. Each bar represents the mean ± SEM of 5–6 rats. Significant difference from normal
control at identical times: ### p < 0.001. No significant difference from CKD control rats at identical times: ns (p > 0.05). Significant difference from
the respective pre-treated value: a p < 0.001. No significant difference from the respective pre-treated value: b (p > 0.05). CUR = Curcumin.
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the CKD control nor the curcumin-treated rats showed
any significant change in body weight compared with their
pre-treated values. On the other hand, CKD control rats
exhibited significant growth retardation (218.0 ± 5.2 g vs
380.4 ± 6.0 g; p < 0.001, n = 6) compared with the normal
control group at the end of the 24 days (Fig. 2 b). How-
ever, the groups of rats treated with the various doses of
curcumin (n = 6) did not show any signs of improvement
in body weight compared with CKD control rats (Fig. 2 b).
Water intake
There was no significant difference in the initial water
intake (31.9 ± 1.1 mL to 31.6 ± 1.4 mL; n = 5 to 6) be-
tween different groups (Fig. 3 a). While the CKD control
rats (n = 6) exhibited a significant increase in water in-
take compared with their pre-treated values (43.3 ± 1.1
mL vs 31.5 ± 1.2 mL; p < 0.001) or with the normal con-
trol group (43.3 ± 1.1 vs 31.9 ± 1.1 mL; p < 0.001) at the
end of the 24 days, neither the normal control nor the
curcumin-treated rats showed any significant change in
water intake compared with their pre-treated values (Fig.
3 b). However, the groups of rats treated with the vari-
ous doses of curcumin (n = 6) showed a significant de-
crease in water intake compared with CKD control rats
(Fig. 3 b).
Food intake
There was no significant difference in the initial food in-
take (19.3 ± 1.4 g to 13.9 ± 1.2 g; n = 6) between the CKD
control and curcumin-treated groups (Fig. 4 a & b).
However, there was a significant difference in the initial
food intake (25.1 ± 1.7 g to 13.9 ± 1.2 g; n = 5 to 6) be-
tween the normal and the CKD control groups (Fig. 4 a
& b). On the other hand, CKD control rats exhibited a
significant (p < 0.001) decrease in food intake (28.3 ± 1.2
g vs 15.1 ± 1.1 g; n = 5–6) compared with the normal
control group at the end of the 24 days (Fig. 4 b). How-
ever, the curcumin-treated groups (n = 6) did not show
significant improvement in food intake compared with
the CKD control group (Fig. 4 b).
Serum total cholesterol
Rats fed with the adenine-supplemented diet (CKD con-
trol rats) alone showed a significant increase (p < 0.001,
n = 6) in total cholesterol level when compared with the
normal control group (n = 5; Table 1). Curcumin treat-
ment produced a significant reduction in total cholesterol
level at doses of 50 (p < 0.01, n = 6), 100 (p < 0.001, n = 6)
and 150mg/kg (p < 0.01, n = 6) compared with the CKD
control rats, although the reduction was not dose-
dependent among the three doses.
Serum triglycerides
The CKD control group showed a significant (p < 0.001,
n = 6) increase in serum triglycerides when compared
with the normal control group (n = 5) at the end of the
treatment (Table 1). Curcumin treatment at the doses of
50 (p < 0.05, n = 6), 100 (p < 0.001, n = 6) and 150 mg/kg
(p < 0.01, n = 6) showed a statistically significant reduc-
tion in serum triglycerides compared to the CKD control
group, although the reduction was not dose-dependent
among the three doses.
Serum HDL cholesterol
Rats fed with the adenine-supplemented diet alone
showed a significant (p < 0.001; n = 6) reduction in HDL
levels compared with the normal control (n = 5) fed with
the standard diet at the end of the 24 days (Table 1).
However, curcumin treatment at the doses of 100 and
150 mg/kg, along with adenine-supplemented diet, pro-
duced a significant (p < 0.05, n = 6) elevation in HDL
cholesterol compared with the CKD control rats.
Serum LDL and VLDL cholesterol
The LDL and VLDL levels were significantly elevated
(p < 0.001; n = 6) in the CKD control rats as compared
with the normal control rats (n = 5; Table 1). Curcumin
treatment showed a significant reduction in LDL choles-
terol at the doses of 50, 100 and 150 mg/kg (p < 0.001,
n = 6) compared with the CKD control rats. On the
other hand, curcumin treatment also showed a signifi-
cant reduction in VLDL cholesterol at the doses of 50
(p < 0.05, n = 6), 100 (p < 0.001, n = 6) and 150 mg/kg
(p < 0.01, n = 6) compared to the CKD control rats.
Serum non-esterified fatty acids (NEFA)
Serum NEFA levels were found to be significantly (p <
0.05) higher in the CKD control group (n = 6) compared
with the normal control rats (n = 5) at the end of the 24
days (Table 1). Curcumin treatment produced a signifi-
cant reduction in serum NEFA at doses of 100 (p < 0.05,
n = 6) and 150 mg/kg (p < 0.01, n = 6) compared with
the CKD control rats.
Atherogenic index (AI) and coronary risk index (CRI)
CKD control rats showed a significant (p < 0.001, n = 6)
elevation of AI and CRI compared with normal control
rats (n = 5; Table 1). On the other hand, the groups
treated with curcumin at the three dose levels showed a
significant (p < 0.001, n = 6) reduction in AI and CRI
when compared with the CKD control rats.
Kidney biochemical parameters
Serum creatinine
The CKD control rats showed a significant increase (p <
0.001, n = 6) in serum creatinine level when compared
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with the normal control group (n = 5). Curcumin treat-
ment produced a significant dose-dependent reduction
(p < 0.01, n = 6) in serum creatine level at doses of 100
and 150mg/kg (p < 0.01, n = 6) compared with the CKD
control rats (Table 2).
Blood urea nitrogen
The blood nitrogen concentration (BUN) in the serum signifi-
cantly increased (p < 0.001, n = 6) in CKD control rats com-
pared with the normal control rats (n = 5). Curcumin
treatment at the doses of 100 and 150mg/kg significantly de-
creased (p < 0.05 and p < 0.01 respectively, n = 6) BUN con-
centration compared with the CKD control rats (Table 2).
Serum albumin
The CKD control rats showed a significant (p < 0.001,
n = 6) reduction of serum albumin level compared with
the normal control rats (n = 5), which was significantly
elevated by the curcumin treatment at the doses of 100
(p < 0.01, n = 6) and 150 (p < 0.05, n = 6) mg/kg at the
end of the 24 day treatment period (Table 2).
Urinary volume
The CKD control group showed a significant (p < 0.001,
n = 6) increase in urinary volume when compared with
the normal control group (n = 5) at the end of treat-
ment. Curcumin treatment at the doses of 100 (p < 0.05,
n = 6) and 150 mg/kg (p < 0.001, n = 6) showed a
Fig. 3 Effect of curcumin on adenine-induced water intake change in rats (A) Daily recordings of the mean water intake changes of the experimental
groups of rats and (B) comparison of the mean water intake of rats prior to (open columns) and after treatment (closed columns) either with the adenine-
supplemented diet alone or with curcumin. Each bar represents the mean ± SEM of 5–6 rats. Significant difference from normal control at identical times:
### p < 0.001. Significant difference from CKD control rats at identical times: *** p < 0.001. Significant difference from the respective pre-treated value: a p<
0.001. No significant difference from the respective pre-treated value: b (p > 0.05). CUR = Curcumin.
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Fig. 4 Effect of curcumin on adenine-induced food intake change in rats (A) Daily recordings of the mean food intake changes of the experimental groups of
rats and (B) comparison of the mean food intake of rats prior to (open columns) and after treatment (closed columns) either with the adenine-supplemented
diet alone or with curcumin. Each bar represents the mean± SEM of 5–6 rats. Significant difference from normal control at identical times: ### p<0.001.
Significant difference from normal control before the treatment: a p<0.001. Significant difference from CKD control rats at identical times: *** p<0.001. No
significant difference from the respective pre-treated value: b (p>0.05). CUR=Curcumin.
Table 1 Effect of curcumin treatment on serum lipid profile changes after 24 days in adenine-induced CKD rats
Parameter Normal
Control
CKD
Control
CUR
(50 mg/kg)
CUR
(100 mg/kg)
CUR
(150 mg/kg)
Total cholesterol (mg/dL) 82.11 ± 8.38 153.28 ± 4.64### 102.46 ± 11.09** 84.74 ± 3.91*** 106.22 ± 13.52**
Triglycerides (mg/dL) 68.59 ± 3.82 109.19 ± 1.71### 85.42 ± 3.09* 65.65 ± 6.37*** 75.70 ± 6.19**
HDL-cholesterol (mg/dL) 35.42 ± 3.10 16.16 ± 3.33### 23.44 ± 1.11ns 29.74 ± 1.11* 28.36 ± 3.41*
LDL-cholesterol (mg/dL) 32.97 ± 14.41 115.28 ± 5.23### 54.81 ± 5.35*** 44.42 ± 4.28*** 46.11 ± 4.09***
VLDL-cholesterol (mg/dL) 13.72 ± 0.76 21.84 ± 0.34### 17.08 ± 0.62* 13.13 ± 1.28*** 15.14 ± 1.24**
NEFA (μEq/L) 872.63 ± 18.03 1099.16 ± 16.36# 810.92 ± 60.81ns 760.55 ± 37.07* 734.97 ± 78.61**
AI 1.31 ± 0.17 10.63 ± 2.28### 3.41 ± 0.48*** 2.22 ± 0.58*** 3.26 ± 1.17***
CRI 2.31 ± 0.17 11.63 ± 2.28### 4.41 ± 0.5*** 3.22 ± 0.2*** 3.10 ± 0.1****
Values represent the mean ± SEM of 5 to 6 rats
Significant difference from normal control: #p < 0.05; ###p < 0.001
Significant difference from CKD control: *p < 0.05; **p < 0.01; ***p < 0.001
No significant difference from CKD control: ns (p > 0.05)
CKD Chronic kidney disease; CUR Curcumin; NEFA Non-esterified free fatty acids
AI Atherogenic index; CRI Coronary risk index
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significant dose-dependent reduction in urinary volume
compared to the CKD control group (Table 2).
Urinary total protein (proteinuria)
The levels of total urinary protein in the CKD control
rats were significantly increased (p < 0.001, n = 6) com-
pared with the normal control rats (n = 5). However, all
three doses of curcumin significantly reduced (p < 0.001,
n = 6) proteinuria compared with the CKD control rats
(Table 2).
Urinary creatinine
The CKD control group showed a significant decrease
(p < 0.001, n = 6) in urine creatinine when compared
with the normal control group (n = 5) at the end of
treatment. Curcumin treatment at the doses of 100 (p <
0.001, n = 6) and 150 mg/kg (p < 0.001, n = 6) showed
statistically significant improvement in urine creatinine
compared to the CKD control group (Table 2).
Urinary urea nitrogen
The urinary urea nitrogen (UUN) concentration was sig-
nificantly reduced (p < 0.001, n = 6) in the CKD control
rats compared with the normal control rats (n = 5). Cur-
cumin treatment at the doses of 100 and 150 mg/kg sig-
nificantly increased (p < 0.05 and p < 0.01 respectively,
n = 6) UUN concentration compared with the CKD con-
trol rats (Table 2).
Creatinine clearance
The level of creatinine clearance calculated by the stand-
ard formula was significantly suppressed (p < 0.001, n =
6) in the CKD control rats compared with the normal
control rats (n = 5; Table 2). However, curcumin
treatment significantly improved creatinine clearance at
the doses of 100 (p < 0.05, n = 6) and 150 mg/kg (p <
0.001, n = 6) compared with the CKD control rats.
Hepatic lipid levels
There was no significant change in liver weight (normal-
ised to body weight) observed among the experimental
groups. Rats fed with adenine-supplemented diet alone
(CKD control rats) showed a significant increase in hep-
atic cholesterol (p < 0.001, n = 6), triglycerides (p < 0.001,
n = 6) and NEFA (p < 0.01, n = 6) compared with the nor-
mal control group (n = 5; Table 3). Curcumin at all the
three doses significantly reduced the hepatic cholesterol
(p < 0.05 to p < 0.001; n = 6), triglycerides (p < 0.01 to p <
0.001; n = 6) and NEFA (p < 0.05 to p < 0.001; n = 6) levels
compared with the CKD control rats.
Discussion
In the present study, we examined the protective effects of
curcumin on hepatic lipid derangement and renal damage
in an adenine-induced rat model of CKD. The long-term
feeding of adenine is known to suppress the excretion of
various nitrogenous compounds due to renal tubular oc-
clusion and produce metabolic abnormalities in rats that
closely mimics CKD in humans [59]. Excess adenine in
mammalian metabolism becomes a significant substrate
for xanthine dehydrogenase and oxidises into low soluble
compounds 2, 8-dihydroxyadenine which further precipi-
tate in renal tubules and damage the kidney tissue accom-
panied by oxidative stress and subsequently renal
dysfunction [60]. The adenine model is reproducible, sim-
pler to conduct and more like human CKD than the 5/6
nephrectomy [61, 62]. Adenine-induced renal damage is
time-dependent-the longer the feeding time, the more se-
vere the renal damage [63]. Previous studies suggested
Table 2 Effect of curcumin treatment for 24 days on serum and urine biomarkers of renal function in adenine-induced CKD rats
Biologic
Fluid
Biomarker Normal
Control
CKD
Control
CUR
(50 mg/kg)
CUR
(100 mg/kg)
CUR
(150 mg/kg)
Serum
Creatinine (mg/dL) 0.45 ± 0.07 2.62 ± 0.08### 2.50 ± 0.15ns 1.71 ± 0.10** 1.27 ± 0.48**
BUN (mg/dL) 4.46 ± 1.53 13.09 ± 1.19## 12.49 ± 2.53 ns 7.14 ± 1.60* 4.99 ± 1.30**
Albumin (mg/dL) 8.41 ± 0.32 5.47 ± 0.08### 6.57 ± 0.27 ns 7.06 ± 0.39** 6.45 ± 0.27*
Urine
Urine volume (mL) 24.40 ± 2.21 37.00 ± 1.58### 32.50 ± 0.92 28.58 ± 1.46*** 25.67 ± 1.17***
Total protein (mg/24 h) 5.52 ± 0.83 70.73 ± 4.14### 25.26 ± 3.07*** 14.82 ± 3.33*** 18.13 ± 2.46***
Creatinine (mg/dL) 28.69 ± 2.61 11.23 ± 0.34### 13.54 ± 0.85 ns 22.72 ± 1.31*** 23.56 ± 2.15***
UUN (mg/dL) 14.28 ± 1.06 5.95 ± 0.75### 8.92 ± 0.82ns 9.96 ± 0.65** 10.01 ± 0.25**
CrCl (mL/min/kg) 3.07 ± 0.20 0.63 ± 0.13### 0.53 ± 0.05 ns 1.37 ± 0.15* 2.03 ± 0.23***
Values represent the mean ± SEM of 5 to 6 rats
Significant difference from normal control: ##p < 0.01; ###p < 0.001
Significant difference from CKD control: *p < 0.05; **p < 0.01; ***p < 0.001
No significant difference from CKD control: ns (p > 0.05)
CKD Chronic kidney disease; CUR Curcumin; BUN Blood urea nitrogen; CrCl Creatinine clearance; UUN Urine urea nitrogen
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that 0.75% w/w adenine in the diet for 4 weeks is an
optimum duration for damage to the renal tissue to occur
without mortality [61, 63]. Furthermore, adenine feeding
for more than 7 weeks has caused significant mortality
[64]. Nevertheless, Aoyama et al. [65] has shown that ad-
enine (0.75% w/w) in the diet produced renal damage re-
sembling CKD but also found 50% mortality. Thus, in the
present study, we used adenine at the dose of 0.75% w/w
in the diet for 24 days and no mortality was found which
is consistent with previous reports [61–64]. Furthermore,
biochemical evaluations in our study have shown that dis-
tinctive CKD was produced in rats upon feeding with ad-
enine. To our knowledge, this is the first study to use
an adenine-induced rat model of CKD to investigate the
protective effects of curcumin on hepatic lipid
metabolism.
In the present study, the body weight of the rats
treated with curcumin was not significantly improved
compared to CKD rats. The reason of the observed dis-
crepancy in the body weight between curcumin-treated
and untreated CKD rats is not clear. The possible
explanation for this discrepancy is decreased food intake
in CKD rats compared to control rats. Moreover, CKD
resulted in impaired triglyceride rich lipoprotein (i.e.
VLDL) metabolism which reduced the fatty acids deliv-
ery to the adipose tissue and limits the capacity to store
energy and thus, contributes to weight loss, wasting and
cachexia in CKD condition [66]. However, in the present
study, curcumin could not reverse the CKD-induced
weight reduction although it alleviated the impaired tri-
glyceride metabolism in CKD rats. Furthermore, CKD
rats increased water intake because the kidneys lose the
capacity to concentrate the urine and excrete more
water (which is evident by the increased urinary volume
of CKD rats). Due to thirst, CKD rats drink more water.
However, curcumin treatment normalised the water in-
take which may be due to its protective effects on kidney
damage and thereby, the kidneys retain the capacity to
concentrate the urine (which is evident by the decreased
urinary volume of curcumin- treated rats).
CKD animals displayed a marked increase in serum
total- and LDL-cholesterol. Serum total cholesterol
elevation may be in part due to the enhanced cholesterol
biosynthesis via up- regulation of the HMG-CoA reduc-
tase enzyme [67, 68] as well as due to a relative reduction
of hepatic cholesterol elimination via down-regulation of
the cholesterol 7α-hydroxylase (CYP7A1) enzyme in CKD
animals [69, 70]. Moreover, increased serum LDL- choles-
terol in the CKD rats could be due to the down-regulation
of LDL receptor in response to CKD [71]. Although the
precise molecular mechanism(s) of LDL-receptor protein
deficiency in CKD have not been fully characterised, pre-
vious studies implicate inefficient translation and/or in-
creased LDL-receptor protein turnover [72, 73]. However,
our results demonstrated that chronic curcumin supple-
mentation to CKD rats effectively reduced the serum and
hepatic total-cholesterol and serum LDL-cholesterol, and
this was found to be consistent with previous studies of
curcumin using various dyslipidaemic animal models [74–
76]. An earlier study demonstrated that curcumin reduced
serum and hepatic cholesterol levels mainly by inhibiting
HMG-CoA reductase enzyme in the liver [77–79]. It is re-
ported that curcumin stimulates CYP7A1 enzymatic activ-
ity by increasing its hepatic gene expression, resulting in
enhanced clearance of cholesterol as bile acids [80]. More-
over, previous studies demonstrated that curcumin up-
regulates the expression of LDL receptor in mouse macro-
phages [81], human hepatoma derived HepG2 cells [82]
and hepatic stellate cells (HSCs) [83]. Hence, the reduc-
tion of LDL-cholesterol by curcumin could be due to the
prevention of the suppressive action of CKD on the LDL-
receptor site. Thus, the constellation of these previous
findings strongly support the results of our study and
the observed cholesterol-lowering efffects of curcumin
could be due to single or multiple effects of curcumin
on potential site(s) of action leading to decreased
cholesterol biosynthesis and/or enhanced elimination
and/or increased hepatic uptake.
Hypertriglyceridaemia is one of the most common
quantitative lipid abnormalities in patients with CKD [5,
84, 85]. Hypertriglyceridaemia in CKD is thought to be
due to the dysregulation of various enzymes such as
lipoprotein lipase (LPL) and hepatic lipase, apolipopro-
teins such as apoC III and apoC II and receptor such as
Table 3 Effect of curcumin treatment on liver weight and lipid levels after 24 days in adenine-induced CKD rats
Parameter Normal
Control
CKD
Control
CUR
(50 mg/kg)
CUR
(100 mg/kg)
CUR
(150 mg/kg)
Liver weight (g/100 g bw) 3.91 ± 0.09 3.61 ± 0.08 3.28 ± 0.23 3.01 ± 0.13 4.32 ± 0.50
Cholesterol (mg/g tissue) 0.38 ± 0.07 4.95 ± 1.30### 2.99 ± 0.28** 2.61 ± 0.15*** 2.53 ± 0.24***
Triglycerides (mg/g tissue) 2.55 ± 0.73 10.51 ± 1.39### 5.00 ± 1.11** 2.65 ± 0.40*** 3.73 ± 0.59***
NEFA (mg/g tissue) 0.73 ± 0.05 1.20 ± 0.06## 0.91 ± 0.11* 0.61 ± 0.07*** 0.89 ± 0.05*
Values represent the mean ± SEM of 5 to 6 rats
Significant difference from normal control: ##p < 0.01; ###p < 0.001
Significant difference from CKD control: *p < 0.05; **p < 0.01; ***p < 0.001
CKD Chronic kidney disease; CUR Curcumin; NEFA Non-esterified free fatty acids;
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VLDL-receptor involved in triglycerides metabolism
[86]. In this study, CKD rats exhibited increased levels of
serum and liver triglycerides (TGs) and serum TG-rich
lipoprotein VLDL. Vaziri and Liang [87] reported that
the deficiency of skeletal muscle, adipose tissue and
myocardium LPL activities may contribute significantly
to the elevation of TGs in CKD. Moreover, hepatic lipase
protein expression and activity is also decreased in CKD
rats [88, 89]. Collectively, lipase deficiency, at least in
part, may be responsible for the apparent increased
serum and hepatic triglyceride levels in CKD animals in
the present study. The VLDL receptor belongs to the
large LDL receptor gene family with distinctly different
ligand specificity and tissue distribution compared with
LDL receptor. It is primarily expressed in skeletal
muscle, myocardium, and adipose tissue [90, 91] where
it binds and internalises triglyceride-rich VLDL particle.
It has been demonstrated that the down-regulation of
VLDL receptor expression is associated with CKD and
nephrotic syndrome together with elevated plasma
VLDL levels [92]. Therefore, in this study, the increased
serum VLDL levels in the CKD rats could be due to
VLDL receptor deficiency.
Our results demonstrated that chronic curcumin
supplementation effectively reduced serum triglycer-
ides and VLDL-cholesterol along with liver triglycer-
ides in accordance with earlier reports [79, 93, 94].
Previously, Seo et al. [95] demonstrated that chronic
curcumin supplementation increased skeletal muscle
LPL activity in db/db mice. More recently, Prabu and
Sumedha [96] reported that a curcumin analogue in-
creased plasma LPL activity in arsenic intoxicated
rats. Thus, in the present study, the reduction in tri-
glycerides levels following curcumin administration
could be due to increased tissue and/or plasma LPL
activity.
Together with hypertriglyceridaemia, CKD is associ-
ated with impaired hepatic fatty acid metabolism. Con-
sistent with previous reports, CKD rats exhibited a
significant elevation of serum and hepatic free fatty acids
in our study. Chronic curcumin administration markedly
reduced the serum and hepatic free fatty acid levels. Al-
though little is known on the effects of CKD on fatty
acid metabolism, it has been demonstrated that curcu-
min decreased lipid accumulation by up-regulating
PPARα while down-regulating various lipogenic genes
such as SREBP1c, acetyl-CoA carboxylase 1 (ACC1),
fatty acid synthase in the liver of mice [97, 98]. Thus,
curcumin may regulate hepatic fatty acid metaboilsm in
CKD by decreasing synthesis and/or increasing catabol-
ism in liver.
The ratio of total cholesterol to HDL serves as a useful
indicator of cholesterol homeostasis in the arterial wall,
glomerular mesangium and liver. The CKD model
employed in the present study exhibited a significant in-
crease in serum total cholesterol-to-HDL cholesterol ra-
tio (CRI), indicating an atherogenic profile. In contrast,
chronic curcumin supplementation to CKD animals nor-
malised total cholesterol-to-HDL cholesterol ratio (CRI)
and AI. Furthermore, CKD is consistently associated
with reduced plasma HDL cholesterol level largely due
to the impaired maturation of cholesterol ester poor
HDL-3 to cholesterol rich HDL-2. In the present study,
CKD rats demonstrated a decreased concentration of
HDL compared to control rats. HDL abnormalities in
CKD are largely due to lecithin–cholesteryl acyltransfer-
ase (LCAT), an important enzyme for HDL maturation,
deficiency [67] and/or reduced expression of hepatic
HDL docking receptor (SR-B1) [99–101]. ATP-binding
cassette transporter A1 (ABCA1) is a membrane associ-
ated protein that mediates transfer of cellular cholesterol
and phospholipids to lipid-poor HDL for disposal in the
liver and, as such, serves as a gatekeeper of reverse chol-
esterol transport pathways [102]. Prabu and Sumedha
[96] reported that arsenic-intoxicated rats chronically
treated with dimethoxycurcumin, a structural analogue
of curcumin, showed increased LCAT activity which also
supports an earlier observation by Tu et al. [103] in
high-fat diet-fed rats. Moreover, Zhao et al. [104] dem-
onstrated that curcumin dose-dependently increased the
protein level of ABCA1 in mouse macrophages but did
not affect the protein expression of SR-BI. Thus, in the
present study, the molecular mechanism(s) of curcumin
to alleviate the HDL abnormalities could be due to the
inhibition of the suppressive action of CKD on LCAT
and/or ABCA1 protein deficiency.
Moreover, in the present study, curcumin failed to
show dose-dependence on lipid parameters measured in
plasma and in the liver and kidney tissues. The values
indicate that the high dose (150 mg/kg) showed more or
less similar size effect (statistically non-significant differ-
ence) as that of the median dose (100mg/kg). As
pointed out by previous researchers, curcumin is poorly
soluble in aqueous solutions and hence, its maximum
solubility in gastric fluids would have been reached with
around 100 mg/kg dose in our study. Thus, one possible
explanation for curcumin’s failure to show dose-
dependent effects could be due to its poor aqueous solu-
bility in gastric fluids leading to inadequate intestinal ab-
sorption and low oral bioavailability [105–107].
Limitations of the present study include evaluating the
protective effects of curcumin only and does not provide
any information on the curative effects of curcumin on
CKD-induced dyslipidaemia. Furthermore, we have de-
duced the molecular mechanism(s) responsible for the
observed changes in lipid metabolism from literature.
Further studies have been undertaken in our laboratory
to explain the mechanism(s) of the hepatic lipid
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metabolism-regulating activities of curcumin (manu-
script in progress).
Conclusion
CKD induced by feeding adenine-supplemented diet to rats
leads to the development of metabolic dyslipidaemia. Long-
term curcumin administration improves metabolic dyslipi-
daemia and shows renoprotective effects in adenine-
induced CKD. Thus, the present findings support the po-
tential therapeutic value of curcumin as a protective phyto-
constituent in attenuating CKD-induced cardiovascular
disease, although further clinical evaluation is required as a
treatment modality.
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